Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Kidney cancer management 3.0: can artificial intelligence make us better?
15
Zitationen
5
Autoren
2021
Jahr
Abstract
PURPOSE OF REVIEW: Artificial intelligence holds tremendous potential for disrupting clinical medicine. Here we review the current role of artificial intelligence in the kidney cancer space. RECENT FINDINGS: Machine learning and deep learning algorithms have been developed using information extracted from radiomic, histopathologic, and genomic datasets of patients with renal masses. SUMMARY: Although artificial intelligence applications in medicine are still in their infancy, they already hold immediate promise to improve accuracy of renal mass characterization, grade, and prognostication. As algorithms become more robust and generalizable, artificial intelligence is poised to significantly disrupt kidney cancer care.
Ähnliche Arbeiten
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
2017 · 15.284 Zit.
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
2012 · 7.745 Zit.
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
2015 · 5.852 Zit.
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
2007 · 5.739 Zit.
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
2007 · 4.777 Zit.